AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy


Features


The U.S. drug trade, especially in the designer drug field, has moved faster than testing can evolve. This is especially true for synthetic cannabinoids, sometimes known as Spice or K2. These drugs are cheap to make and can be cut into other illegal drugs such as opioids, leading to mass…
High-density lipoprotein has been thought of as the good lipoprotein for its transporting cholesterol out of the blood stream and its association with lower cardiovascular disease risk. But the failure of HDL-lifting drugs along with emerging research findings are shedding new light on this complex molecule, its measurement and interpretation.

Ask the Expert


No pharmaceutical agent targeting Lp(a) is yet FDA-approved. Nevertheless, Lp(a) testing identifies individuals with increased cardiovascular disease risk who would not be recognized otherwise and enables them to benefit from rigorous treatment for other CVD risk factors.

Bench Matters


Federal Insider


Focus on Mass Spectrometry


Industry Playbook


Regulatory Roundup


The Sample


A new analysis of accidental drug poisonings found a nearly 40-year straight uphill rise in annual mortality rates from unintentional overdoses of all drug classes. The unending increase, which predates the current opioid epidemic, underscores the complexity of drug dependence and underscores the need to look beyond controlling specific drugs…